Neurotech International

Neurotech is a clinical-stage biopharmaceutical development company focused on paediatric neurological disorders.

[Neurotech International @NeurotechInt]

Thank you to everyone who joined us at Neurotech’s Investor & Advocacy Day yesterday.

It was a special afternoon bringing together families, medical professionals, advocates and the Neurotech team to share experiences, discuss NTI164 and hear firsthand about the impact the treatment is having on patients and their families.

We’re grateful to the families who shared their stories and to everyone who took the time to be part of the day.
$NTI

[Neurotech International @NeurotechInt]

We’re looking forward to attending the Gold Coast Investment Showcase on 11 and 12 June 2026 at the JW Marriott Gold Coast Resort & Spa, Queensland.

Managing Director and CEO Dr Anthony Filippis will present on Thursday, 11 June at 12:00 pm, providing an update on Neurotech’s recent progress and upcoming milestones.

For conference information and registration:
https://t.co/9IZ8TbYWmJ

#NTI #Neurotech @VEvents_RIU #Biotech

[Neurotech International @NeurotechInt]

REMINDER | We’re hosting our Neurotech Investor & Advocacy Day on 21 May 2026. Join us for a meaningful gathering of families, professionals and community advocates to hear from the team behind Neurotech, alongside medical professionals and families sharing insights into NTI164 and the impact the treatment is having on patients and their lives.
The event is an opportunity to connect, learn and support the children and families who need it most.

Canapés and light refreshments will be served following the presentations.

To reserve your place, RSVP $NTI by 14 May 2026 to [email protected].
#Neurotech #Investors #Biotech

[Neurotech International @NeurotechInt]

We’re hosting our @NeurotechInt Investor & Advocacy Day on 21 May 2026. Join us for a meaningful gathering of families, professionals and community advocates to hear from the team behind Neurotech, alongside medical professionals and families sharing insights into NTI164 and the impact the treatment is having on patients and their lives.

The event is an opportunity to connect, learn and support the children and families who need it most.

Canapés and light refreshments will be served following the presentations.

To reserve your place, RSVP by 14 May 2026 to [email protected].

$NTI #Neurotech #Investors #Biotech

[Neurotech International @NeurotechInt]

We’ll be presenting at the 1st Australian Microcap Investment Conference in Sydney on Monday, 11 May.
MD and CEO Dr Anthony Filippis will present at 3:00 pm, providing an overview of Neurotech’s strategy, clinical progress and growth outlook.

Fullerton Hotel, Sydney
Monday, 11 May 2026

To register: https://t.co/wcKUI3bdtP

#AusMicrocap #Biotech #ASX $NTI

[Neurotech International @NeurotechInt]

Watch Managing Director and CEO Dr Anthony Filippis provide a brief update from the Ignite Summit in Hong Kong, outlining Neurotech’s recent clinical and corporate milestones and the next stage of delivery.

$NTI #ASX #SmallCaps #CapitalMarkets #Mining #MarketOpen #IgniteSummit #IgnitePartners

[Neurotech International @NeurotechInt]

Our Quarterly Activities Report for the period ending 31 March 2026 has been released.
View the full $NTI report: https://t.co/OxLUfj1mTt

[Neurotech International @NeurotechInt]

Our CEO & Managing Director, Dr Anthony Filippis, presented at the Ignite Investment Summit Hong Kong last week, where he discussed Neurotech’s progress advancing NTI164.

A replay of the presentation is now available: https://t.co/airaDPveSq

$NTI #Neurotech #Autism #ASD #Biotech #Ignite #Conference

[Neurotech International @NeurotechInt]

Biocurious: Stay tuned as drug developers get to the pointy end of their efforts | Media coverage by @StockheadAU

https://t.co/MbFP2arSfz

$NTI #Neurotech #Autism #ASD #Biotech

[Neurotech International @NeurotechInt]

We’re proud to share that our U.S. Medical Advisor, Dr Bonni Goldstein, MD has been appointed to the newly formed National Compassionate Care Council.

The Council is focused on U.S. cannabis and healthcare policy reform and will be responsible for activities spanning informing policy, clinical practice, research and patient access.

Its mandate includes providing clinical and scientific guidance to inform the safe and appropriate use of medical cannabis, developing frameworks to support cannabis as a recognised therapeutic option, and promoting the use of real-world data and clinical evidence to guide dosing, safety, and efficacy considerations.

We look forward to the meaningful contributions Dr Goldstein will make in advancing a more accessible, equitable, and evidence-based framework for cannabinoid-based therapies.

Read the full Media Release here: https://t.co/8TNmiPjQzD

#Neurotech #ASX $NTI #DrBonniGoldstein #CannabisMedicine #HealthcarePolicy #ClinicalEvidence #PatientAccess #CannabinoidTherapies

[Neurotech International @NeurotechInt]

We’ve wrapped up our time at the Ignite Investment Summit Hong Kong, where our CEO & Managing Director, Dr Anthony Filippis, presented Neurotech’s progress advancing NTI164.

The Summit provided a great opportunity to meet with investors and discuss NTI164, our novel broad-spectrum oral cannabinoid therapy being developed for childhood neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome and PANDAS/PANS.

We thank Ignite Partners, the organisers, and everyone who took the time to meet with us during the conference. $NTI

[Neurotech International @NeurotechInt]

REMINDER | Our CEO & MD, Dr Anthony Filippis, is attending the Ignite Summit HK in Hong Kong, hosted at the Grand Hyatt, Wan Chai.

Dr Filippis will be presenting on Day 1, Wednesday 15 April at 3:10pm, sharing an update on Neurotech’s clinical development programs and the advancement of NTI164 in paediatric neurological disorders.

If you are attending the Summit, we welcome the opportunity to connect.

#IgniteInvestmentSummit #HongKong #InvestorMeetings #LifeSciencesInvestment #Neurotech #ASX #NTI #IgniteSummitHK #Biotechnology #PaediatricNeurology

[Neurotech International @NeurotechInt]

We’re presenting at the Ignite Investment Summit in Hong Kong this week, with our CEO & MD, Dr Anthony Filippis, representing Neurotech. Anthony will discuss NTI164, our broad-spectrum oral cannabinoid therapy, and its development as a novel therapy for childhood neurological and neurodevelopmental disorders.

He will deliver a group presentation at 3:10pm HKT / 5:10pm AEST on Wednesday 15 April 2026, alongside a series of investor meetings across the Summit.

If you are attending, we look forward to connecting.
$NTI Presentation: https://t.co/jLHjsbnKVE

[Neurotech International @NeurotechInt]

Neurotech opens first site for phase III autism trial | $NTI Media coverage The Australian.
https://t.co/zG8T5dewu3
#Neurotech #NTI #Autism #ASD #Biotech

[Neurotech International @NeurotechInt]

In case you missed it, our CEO & Managing Director, Dr Anthony Filippis, recently presented at the NWR Healthcare Conference, outlining clinical outcomes from NTI164 in Autism Spectrum Disorder.

As Anthony noted, “We’ve shown that 84% of patients showed improvement within the first eight weeks of treatment with NTI164.”

In the Phase II/III clinical trial, NTI164 demonstrated clinically meaningful improvements across core ASD symptom domains, including social responsiveness, anxiety, behaviour and communication.

These outcomes continue to support NTI164's advancement into the pivotal Beyond Harmony Phase 3 clinical study, as we progress toward regulatory pathways in Australia and the United States.

Watch the full $NTI replay here: https://t.co/lBfgTFlbpo

[Neurotech International @NeurotechInt]

Our CEO & MD, Dr Anthony Filippis, will be attending the upcoming Ignite Summit HK in Hong Kong, hosted at the Grand Hyatt, Wan Chai.

Dr Filippis will be presenting on Day 1, Wednesday 15 April at 3:10pm, sharing an update on Neurotech’s clinical development programs and the advancement of NTI164 in paediatric neurological disorders.

If you are attending the Summit, we welcome the opportunity to connect.
$NTI

[Neurotech International @NeurotechInt]

On 2 April, we recognise World Autism Awareness Day.
At Neurotech, we're advancing NTI164 through clinical development in Autism Spectrum Disorder, with a focus on addressing core symptoms and underlying neuroinflammatory pathways. The Beyond Harmony Phase 3 clinical study is now underway, designed to support regulatory submissions in Australia and the United States.

We remain focused on developing new treatment options for children and families affected by ASD.

Learn more about World Autism Understanding Month here: https://t.co/YkOkNdSj0d

#WAUM2026 $NTI #WorldAutismAwarenessDay #AutismSpectrumDisorder #Neurotech #ASXNTI #ClinicalTrials #PaediatricNeurology #Autism

[Neurotech International @NeurotechInt]

Autism data hits ‘registration benchmark’ as Neurotech prepares for Phase III clinical trial | Media coverage by @cannabiz_au.
https://t.co/xwXPRfLmCj
$NTI #Neurotech #Autism #ASD